These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16511430)

  • 61. Hypersensitivity reactions due to abacavir.
    Newsline People AIDS Coalit N Y; 1998 Feb; ():35-6. PubMed ID: 11367446
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
    de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS
    AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818
    [No Abstract]   [Full Text] [Related]  

  • 63. Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.
    Boyle BA; Elion R; Cohen CJ; DeJesus E; Hawkins T; Moyle GJ
    AIDS Read; 2007 Oct; 17(10):484-90. PubMed ID: 17990370
    [No Abstract]   [Full Text] [Related]  

  • 64. The abacavir hypersensitivity reaction: a review.
    Clay PG
    Clin Ther; 2002 Oct; 24(10):1502-14. PubMed ID: 12462283
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Agranulocytosis induced by abacavir.
    Tikhomirov V; Namek K; Hindes R
    AIDS; 1999 Jul; 13(11):1420-1. PubMed ID: 10449302
    [No Abstract]   [Full Text] [Related]  

  • 66. Clinical and immunogenetic correlates of abacavir hypersensitivity.
    Phillips EJ; Wong GA; Kaul R; Shahabi K; Nolan DA; Knowles SR; Martin AM; Mallal SA; Shear NH
    AIDS; 2005 Jun; 19(9):979-81. PubMed ID: 15905681
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management protocol for abacavir-related hypersensitivity reaction.
    Clay PG; Rathbun RC; Slater LN
    Ann Pharmacother; 2000 Feb; 34(2):247-9. PubMed ID: 10676833
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
    Linde M
    Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759
    [No Abstract]   [Full Text] [Related]  

  • 69. Genetic testing may avoid abacavir hypersensitivity reaction.
    James JS
    AIDS Treat News; 2006; (419):6-7. PubMed ID: 17096489
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vertigo and abacavir.
    Fantry LE; Staecker H
    AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Abacavir and cardiovascular risk: reviewing the evidence.
    Costagliola D; Lang S; Mary-Krause M; Boccara F
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan.
    Kurita T; Kitaichi T; Nagao T; Miura T; Kitazono Y
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):361-71. PubMed ID: 24585486
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Risk factors for Abacavir-induced hypersensibility syndrome in the "real world"].
    Chirouze C; Hustache-Mathieu L; Rougeot C; Drobacheff C; Gil H; Faller JP; Lebrun C; Estavoyer JM; Hénon T; Hoen B
    Pathol Biol (Paris); 2004 Nov; 52(9):529-33. PubMed ID: 15531117
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Abacavir and diabetes.
    Modest GA; Fuller J
    N Engl J Med; 2001 Jan; 344(2):142-4. PubMed ID: 11188420
    [No Abstract]   [Full Text] [Related]  

  • 75. Complications and side effects. Abacavir hypersensitivity testing results--Montreal.
    TreatmentUpdate; 2007; 19(5):8-9. PubMed ID: 17955617
    [No Abstract]   [Full Text] [Related]  

  • 76. More on abacavir-induced neuropsychiatric reactions.
    Foster R; Taylor C; Everall IP
    AIDS; 2004 Dec; 18(18):2449. PubMed ID: 15622330
    [No Abstract]   [Full Text] [Related]  

  • 77. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812
    [No Abstract]   [Full Text] [Related]  

  • 78. Tolerability of abacavir in the clinical setting.
    Martín-Carbonero L; Barreiro P; Soriano V; González-Lahoz J
    Clin Microbiol Infect; 2000 Nov; 6(11):621-2. PubMed ID: 11168068
    [No Abstract]   [Full Text] [Related]  

  • 79. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.
    El-Sahly HM
    AIDS; 2004 Jan; 18(2):359-60. PubMed ID: 15075569
    [No Abstract]   [Full Text] [Related]  

  • 80. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
    Kowalska JD; Kirk O; Mocroft A; Høj L; Friis-Møller N; Reiss P; Weller I; Lundgren JD
    HIV Med; 2010 Mar; 11(3):200-8. PubMed ID: 19863618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.